anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was designed as a randomized controlled experimental study with the aim of examining the effect of affirmation and massage applied by mothers and fathers to their infants on their infants' sleep quality and maternal-paternal attachment. Infants aged 0-6 months will be included in the study. In the study, 15 babies (d=0.80, G=0.80, p=0.05) will be randomly selected for each group, Experimental Group 1: The Group To which the Mother Applies Affirmation and Massage (A), Experimental Group 2: The Group To which the Father Applies Affirmation and Massage (B) and Control Group (C) will be determined as three groups. Some criteria will be considered in infants selected and not selected into groups.

Experimental Group 1: Mothers in Group (A) Affirmation and Massage, Experimental Group 2: Fathers in Group (B) Affirmation and Massage, 3 days a week for 15 minutes, will be taught to apply affirmation and massage. Affirmation and massage applications will be shown once in the practice hall of the center as an example for the mother and father to be applied to their baby. Afterwards, affirmation and massage applications will be applied by the mother and father at the baby's home. After 5 weeks, the experimental and control groups will be invited to the center and the results will be compared by measuring with the data collection tools again.
OBJECTIVES: I. Determine the maximum tolerated dose of T138067 sodium that can be given to patients with advanced refractory cancer on a 28-day schedule and establish a dose for further study. II. Evaluate the safety and dose limiting toxicity of T138067 sodium in these patients. III. Determine the pharmacokinetic parameters after a single intravenous dose of this agent in these patients. IV. Obtain safety data and preliminary efficacy information after repetition of single doses of T138067 sodium in these patients.

OUTLINE: This is an open label, dose escalation study. Patients receive T138067 sodium by IV over 3 hours. Patients may be retreated every 4 weeks for up to 6 courses (6 months total) in the absence of disease progression or dose limiting toxicity (DLT). At least 3 patients are treated at each dose level in the absence of DLT. The maximum tolerated dose is defined as the dose level where 2 of 3-6 patients experience DLT.

PROJECTED ACCRUAL: Approximately 3-24 patients will be accrued into this study.
Soybean cyst nematode (Heterodera glycines, soybean cyst nematode [SCN]) disease adversely affects the yield of soybean and leads to billions of dollars in losses every year. To control the disease, it is necessary to study the resistance genes of the plant and their mechanisms. Isoflavonoids are secondary metabolites of the phenylalanine pathway, and they are synthesized in soybean. They are essential in plant response to biotic and abiotic stresses. In this study, we reported that phenylalanine ammonia-lyase (PAL) genes GmPALs involved in isoflavonoid biosynthesis, can positively regulate soybean resistance to SCN. Our previous study demonstrated that the expression of GmPAL genes in the resistant cultivar Huipizhi (HPZ) heidou are strongly induced by SCN. PAL is the rate-limiting enzyme that catalyzes the first step of phenylpropanoid metabolism, and it responds to biotic or abiotic stresses. Here, we demonstrate that the resistance of soybeans against SCN is suppressed by PAL inhibitor l-α-(aminooxy)-β-phenylpropionic acid (L-AOPP) treatment. Overexpression of eight GmPAL genes caused diapause of nematodes in transgenic roots. In a petiole-feeding bioassay, we identified that two isoflavones, daidzein and genistein, could enhance resistance against SCN and suppress nematode development. This study thus reveals GmPAL-mediated resistance against SCN, information that has good application potential. The role of isoflavones in soybean resistance provides new information for the control of SCN. [Formula: see text] Copyright © 2024 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reaction of nitroglycerin ointment 0.4% applied to the anal canal is headache.

Headache may be recurrent following each dose. Headaches are typically of short duration and can be treated with an analgesic, e.g. acetaminophen, and are reversible upon discontinuation of treatment.

In Study REC-C-001, a double-blind, placebo-controlled trial in patients with a painful chronic anal fissure, the most frequent (≥ 2%) adverse reactions reported were as follows (Table 1):
OBJECTIVES: Repetitive Transcranial Magnetic Stimulation (rTMS) is considered as a safe and non-invasive developing technique used as a therapeutic method for patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who suffer from disturbances in gait and balance. The aim of our study is to evaluate the long-term effect of high frequency rTMS as a therapeutic option for truncal ataxia in RRMS patients and to assess its impact on the integrity of the white matter (WMI), measured in the form of anisotropy metrics using diffusion tensor imaging (DTI).
METHODS: The study was conducted in two phases: phase I; a randomized, single-blind, sham-controlled phase and phase II was a 12 months longitudinal open-label prospective phase. Phase I of the trial involved the randomization of 43 patients with RRMS and truncal ataxia to either real (n = 20) or sham (n = 19) rTMS (2 participants from each treatment group were excluded from the study; one developed a relapse before treatment, 2 declined to participate, and one did not show up). Phase II involved providing 12 actual treatments cycles to all patients; each cycle length is 4 weeks, repeated four times on a trimonthly basis, forming a total of 48 sessions. DTI was used for assessment of the WMI. All patients performed DTI 3 times: Imaging sessions were conducted at the screening visit, at the end of phase I, and after the last session in phase II for the first, second and third sessions respectively. A figure-of-8-shape coil, employing rTMS protocol and located over the cerebellum, was used. rTMS protocol is formed of 20 trains formed of 50 stimuli with 20 s apart (5 Hz of 80 % of resting Motor Threshold "MT"). The Berg Balance Scale (BBS), Time up and go (TUG) test, and 10-m walk test (10MWT) were first evaluated at the start of each cycle and just after the final rTMS session.
RESULTS: The genuine rTMS group's 10MWT, TUG, and BBS showed substantial improvement (p < 0.01), which is continued to be improved throughout the study Timeline, with a significant difference observed following the final rTMS session (P< 0.001). A longitudinal increase in FA was observed in both the Cerebello-Thalamo-Cortical (CTC) and Cortico-Ponto-Cerebellar (CPC) bilateral, as indicated by means of Fractional Anisotropy (FA) measures (p < 0.05).
CONCLUSION: In ataxic RRMS patients, high frequency rTMS over the cerebellum has a long-term beneficial impact on both balance and WMI.
The invention provides a sodium ozagrel sodium chloride injection and a preparation method thereof and belongs to the technical field of medicines. The invention aims to overcome the defects that a traditional sodium ozagrel raw material is high in cost and cannot meet the market demand, and moreover, the preparation technology is complicated due to the fact that sodium ozagrel and the sodium ozagrel sodium chloride injection are separately prepared. The injection comprises the following components in parts by weight: 70-75 parts of ozagrel, 140-150 parts of glycine, 5-15 parts of citric acid, 25-35 parts of sodium hydroxide and 850-900 parts of sodium chloride. The invention also provides the preparation method for the sodium ozagrel sodium chloride injection. The sodium ozagrel sodium chloride injection provided by the invention is high in stability and is obtained by directly synthetizing the sodium ozagrel during the preparation process. The raw material is low in cost, the technical process is simple, and the cost is low.
Pre-test Forms were applied and data were obtained.No attempt has been made. This group received routine training and follow-ups at the family health center and premarital counseling unit.At the end of the 10th week, the post-test forms were applied and the data were obtained.
The invention discloses a medicine used for treating women postpartum diseases. The medicine is mainly prepared from the raw materials of, by weight: 20g of Chinese rose, 15g of banksian rose, 0.5g of ginseng, 20g of tuckahoe, 30g of incised notopterygium rhizome and root, 10g of licorice root, 15g of Szechwan lovage rhizome, 30g of ligusticum, 400g of motherwort, and 50g of white peony root. The 10 traditional Chinese medicines are mixed and grinded into fine powder; honey is added into the powder, and the mixture is prepared into pills with weights of 8g. On pill is taken one day, and the pills are taken with yellow rice wine. The medicine has the functions of qi nourishing, blood supplementing, liver soothing, qi regulating, tendon soothing, meridian activating, blood circulation activating, stasis removing, tranquilizing, nerve soothing, bleeding stopping, and pain relieving. With the medicine, diseases such as postpartum hemorrhage, postpartum infection and fever, postpartum convulsions, postpartum headache and dizziness, postpartum abdominal pain, and the like can be treated, and various incurable chronic gynecological diseases can also be treated. An effective rate can be higher than 95%, and a curative rate can be higher than 90%.
FIELD: pharmaceutical engineering. SUBSTANCE: method involves working with fine dispersed powder of medical preparation having particle size less than 10 mcm and low yield point by agglomerating the fine dispersed powder of medical preparation in pushing the medical preparation powder through agglomerator unit by means of mechanical driven rotor device having agglomerator unit having U-shaped sieve member. The produced agglomerates are spheroidized and sorted according to their sizes. The device has agglomerator unit, spheroidizing unit being inclined granulating bin with one or several scrubbers and circumferential speed of 0.5-1.0 m/s and sieve unit for sorting agglomerates according to their sizes. Finished medical preparation is composed of agglomerates having specific surface of 2-20 mg/g. EFFECT: improved production process with no binding material needed; provided satisfactory viscosity and low cohesion coefficient in inhalation device. 15 cl, 7 dwg
FIELD: organic chemistry. SUBSTANCE: product: derivative of cauloside C of the formula. Reagent 1: cauloside C. Reagent 2: KOH. Reaction is carried out in medium of ethyl alcohol. Synthesized compound is low toxic, shows thermostable property and good solubility in water. Compound is used in medicine for burns and wounds treatment. EFFECT: improved method of synthesis.
1340929 Salicylamide preparations ALZA CORP 19 April 1971 [23 March 1970 30 Sept 1970] 25004/71 Heading A5B An orally administrable dosage unit having analgesic, antipyretic, anti-inflammatory and/or sedative activity comprises an alkali metal or alkaline earth metal salt of salicylamide and a carrier therefor. The unit may also include an alkali metal or alkaline earth metal salt of p-acetylaminophenol. It may be in the form of a tablet, pill or capsule. In one embodiment, the unit may have a coating which is resistant to gastric juices but soluble in the small intestine. In another, it may include an effervescent couple, e.g. sodium bicarbonate/ tartaric acid/citric acid and a nucleating inhibitor, e.g. polyvinyl pyrrolidone, methyl cellulose or gelatin.
To perform TR Band Compression Device (Screw Type) placement after radial arterial line removal, position the patient with the forearm and wrist exposed, ensuring privacy. Place an absorbent pad under the area and clean the puncture site with povidone. Withdraw the radial arterial line by 2-3 cm and secure the TR Band Compression Device with the strap, ensuring it is tight enough to prevent spinning. Adjust the screw cap to control pressure, gradually removing the line while maintaining hemostasis. Use the reverse Barbeau's test to confirm radial artery patency and adjust pressure as needed. After bleeding stops, unfasten the band while stabilizing the site, clean any blood, and apply a sterile gauze dressing. Reassess hand perfusion to ensure adequate blood flow.
During this procedure a 50 mm or 100 mm long (dependent on body habitus), 18-gauge conventional cannula with a straight 5 mm active tip will be placed parallel and oblique to the targeted medial branch branches (the nerves carrying pain signals from the facet joints). At each location, one lesion will be made to accommodate anatomic variation.
Intravenous infusions should be made slowly over a period of not less than 15 minutes, 30 minutes before beginning cancer chemotherapy and repeated every 2 hours for two doses, then every 3 hours for three doses. 

The initial two doses should be 2 mg/kg if highly emetogenic drugs such as cisplatin or dacarbazine are used alone or in combination. For less emetogenic regimens, 1 mg/kg per dose may be adequate. 

For doses in excess of 10 mg, metoclopramide injection should be diluted in 50 mL of a parenteral solution. 

The preferred parenteral solution is Sodium Chloride Injection (normal saline), which when combined with metoclopramide injection, can be stored frozen for up to 4 weeks. Metoclopramide injection is degraded when admixed and frozen with Dextrose-5% in Water. Metoclopramide injection diluted in Sodium Chloride Injection, Dextrose-5% in Water, Dextrose-5% in 0.45% Sodium Chloride, Ringer's Injection, or Lactated Ringer's Injection may be stored up to 48 hours (without freezing) after preparation if protected from light. All dilutions may be stored unprotected from light under normal light conditions up to 24 hours after preparation. 

If acute dystonic reactions should occur, inject 50 mg Benadryl® (diphenhydramine hydrochloride) intramuscularly, and the symptoms usually will subside.
Remote computing analysis for cognitive state data metrics is performed. Cognitive state data from a plurality of people is collected as they interact with a rendering. The cognitive state data includes video facial data collected on one or more local devices from the plurality of people. Information is uploaded to a remote server. The information includes the cognitive state data. A facial expression metric based on a plurality of image classifiers is calculated for each individual within the plurality of people. Cognitive state information is generated for each individual, based on the facial expression metric for each individual. The cognitive state information for each individual within the plurality of people who interacted with the rendering is aggregated. The aggregation is based on the facial expression metric for each individual. The cognitive state information that was aggregated is displayed on at least one of the one or more local devices.
Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
Obese individuals with Type 2 Diabetes or insulin resistance who have been recently prescribed Metformin and have a Body Mass Index (BMI) ≥ 85th percentile for age/sex (n=20) will be recruited. Participants in this cohort will be asked to complete a two study visits approximately 6 months apart.
Patients will receive a preoperative ultrasound-guided pericapsular nerve group block with 20 mL of 0.5% ropivacaine. Using appropriate sterile precautions and procedural sedation with up to 2 mg IV midazolam, an ultrasound (Mindrey TE9) equipped with either a linear 15-6 megahertz (MHz) or a curvilinear 5-2 MHz transducer (habitus-dependent) used to identify the anterior inferior iliac spine, iliopubic eminence, and psoas muscle. After spinal anesthesia, a 22g 80 mm echogenic block needle (Stimuplex Ultra 360) is advanced lateral to medial, in the plane with the ultrasound beam, beneath the psoas tendon to the iliopubic eminence. 20 mL 0.5% ropivacaine is injected beneath the psoas tendon and above the iliopubic eminence in 5 mL increments with a periodic aspiration to prevent intravascular injection. The needle is withdrawn, and the needle entry site is wiped clean.
<P>PROBLEM TO BE SOLVED: To provide a solid agent for dialysis, in which sodium bicarbonate is surely coated with an inactive ingredient, capable of preventing reaction of sodium bicarbonate with an electrolyte, etc. and being readily produced and to provide a method for producing the solid agent for dialysis.  <P>SOLUTION: It was found to produce a strong coating layer even in a single layer by binding an electrolytic component in a sufficient amount to glucose. As a result, the thick and strong coating layer can be prepared by binding other electrolytic component to glucose when a mixture containing glucose and the electrolytic component as an inert component is applied to the surface of sodium bicarbonate. Since a coating layer by the thick and strong inert component can be provided thus, exposure of sodium bicarbonate in places in which the coating layer is not sufficient can be prevented and it can be prevented to bring sodium bicarbonate into contact with an electrolyte and a pH adjuster.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A wearable sensor apparatus is disclosed that includes a flexible substrate adapted to be coupled with a skin surface of an expectant mother. A conductor is disposed on the flexible substrate. The conductor can include micron-scale invaginations. The conductor can be capable of repeatable variation in resistance when subject to a strain. Also disclosed is a system for monitoring the health of a fetus in utero that includes a wearable sensor apparatus. The wearable sensor apparatus is configured to output a signal responsive to an electrical input. The system includes a computing system with one or more hardware processors. The computing system is programmed to implement a signal processing module configured to access the output signal from the wearable strain gauge and generate an output indicative of health of the baby in utero. The output can be based in part on the received output signal and previously stored correlations between signal data from the wearable strain gauge and observations of the system or of the mother. A user interface module can be provided and can be configured to display an output indicative of health of the baby in utero.
Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention concerns a combination of the first component (a) that is a reuptake inhibitor of 5-HT with the second component (b) that is a selective antagonist of 5-HT 1A  of the formula (I)   where R 1  means n-propyl or cyclobutyl; R 2  means isopropyl, tert. -butyl, cyclobutyl, cyclopentyl or cyclohexyl; R 3  means hydrogen atom; R 4  means hydrogen atom or methyl in the form of (R)-enantiomer as a free base or its pharmaceutically acceptable salts. Invention relates to also its synthesis, pharmaceutical preparations containing the indicated combination used for treatment of affective disorders. The described composition is more effective in treatment of affective states. EFFECT: valuable properties of inhibitor, enhanced effectiveness of combination. 19 cl, 1 dwg, 9 ex
Shoulder stabilization exercises will be given to the experimental group participants individually during 8 weeks. Exercises will be done 3 times a week and each exercise will be performed with 10 repetitions, 3 sets and 60-90 seconds rest between sets. Also experimental group participants will do office exercise training that given to other group participants.
Bronchiectasis often demonstrates decreased exercise tolerance, marked dyspnea and fatigue. The causes are multifactorial and include altered pulmonary mechanics, inefficient gas exchange, decreased muscle mass, and psychological status, which all lead to a progressive detraining effect. Essentially both the pathology and the functional manifestations of bronchiectasis increase the demand for inspiratory muscle work and that contribute to dyspnea and exercise limitation.

In recent studies reduced strength of respiratory muscles are investigated in bronchiectasis and can be contribute the exercise limitation. Additionally IMT has shown to improve respiratory muscle function, exercise tolerance and dyspnea in patients with bronchiectasis. Despite this, the number of studies are inadequate and so the optimal training protocol remains still to be defined. In this study the researchers want to investigate the effects of high-intensity inspiratory muscle training in functional results in patients with bronchiectasis.
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
The invention comprises a modified lanolin especially suited for use on the skin and substantially free from side reaction materials, characterized in that 40 to 100 per cent of the lanolin hydroxyl groups have been removed by acylation and a process for producing a modified lanolin which comprises acylating lanolin with an acid or acid anhydride, such as acetic anhydried, propionic anhydride, benzoic anhydride or ricinoleic acid, removing the excess acylating agent by washing and purifying by vacuum distillation.  The acylation is preferably performed in an inert atmosphere, e.g. nitrogen. Examples describe the production of lanolin derivatives in which acylation is effected with acetic anhydride, propionic anhydride, benzoic anhydride, and ricinoleic acid.  Also mentioned are derivatives obtained by employing undecylenic, salicyl and p-aminobenzoyl acylating agents.ALSO:The invention comprises a solution of an acylated lanolin (see Group IV (b)) dissolved in at least 10 times its weight of mineral oil to form a clear solution at 25 DEG  C.  The propionate and undecylenate have fungicidal properties, the benzoate has antiseptic action, the salicylate has analgesic properties and the p-aminobenzoate has sun-screen activity. Other uses are in hair brilliantines, lipsticks, pharmaceutical preparations and baby oils.  The compounds can also be employed in emulsions.  Also mentioned are the acetate, benzoate and ricinoleate of lanolin.
All enrolled cases should be given standard chemotherapy, radiotherapy and endocrine therapy according to the Chinese Society of Clinical Oncology (CSCO) guidelines for the treatment of breast cancer, with the specific regimen decided by the doctor according to the condition. After the completion of standard chemotherapy, capecitabine 1250mg/m2 should be given orally twice a day for 2 weeks of the 3-week treatment course, and the total duration of treatment is 8 courses, which can be given simultaneously with radiotherapy and endocrine therapy. Premenopausal patients may use ovarian suppressants as needed.